Patent · US Active

C10-substituted camptothecin analogs

US7687497B2 · kind B2 · utility

0Cited by
4References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 16, 2007
Grant dateMar 30, 2010
Priority date
Expiry dateOct 16, 2027

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.